Skip to main content

Table 1 Alternative splicing signatures associated with overall survival in patients with HNSC

From: Prognostic role of alternative splicing events in head and neck squamous cell carcinoma

AS type

Formula

HR (95% CI)

AUC

AA

(AGTRAP|670|AA × − 2.12)+(RNMT|44751|AA × − 3.18)+(PTGR1|87219|AA × − 4.27)+(DSN1|59309|AA × − 10.59)+(C19orf60|48492|AA × − 2.08)+(MDM1|22932|AA × 1.56)+(RAD23A|47892|AA × − 2.79)+(SYNE2|27845|AA × 2.23)+(TMEM134|17234|AA × − 2.65)+(TJAP1|76276|AA × − 1.27)+(STX1A|80019|AA × − 5.92)+(NRBP1|53010|AA × − 4.98)+(HSD17B7|8758|AA × 1.98)+(BUB3|13390|AA × 1.63)

3.716 (2.740–5.039)

0.758

AD

(ALG3|67856|AD × − 1.51)+(TCIRG1|17286|AD × − 4.93)+(SMIM4|65231|AD × − 5.2)+(GPS1|44273|AD × − 14.83)+(ABCB8|82291|AD × − 3.26)+(TMEM205|47659|AD × − 2.3)+(FCF1|28425|AD × 2.31)+(FDPS|8075|AD × 2.5)+(TMEM134|17238|AD × − 4.29)+(KRIT1|80429|AD × − 0.78)+(DCTN3|86188|AD × − 0.48)+(MRM1|40499|AD × 9.4)+(DDX11|20979|AD × 3.86)+(ATG16L1|58040|AD × 4.86)

3.544 (2.625–4.784)

0.743

AP

(SH3KBP1|88642|AP × − 1.08)+(PACS2|29633|AP × − 3.7)+(B3GNTL1|44424|AP × 0.74)+(SLC25A45|16820|AP × − 1.41)+(PKN1|47976|AP × − 0.75)+(C5orf30|72920|AP × − 2.54)+(APIP|14963|AP × − 2.68)+(TSC2|33190|AP × − 8.59)+(LEF1|70286|AP × 1.73)+(CNTRL|87406|AP × − 1.32)

3.384 (2.509–4.564)

0.716

AT

(RBPMS|83289|AT × 2.65)+(MOBP|64191|AT × − 0.87)+(C15orf57|29992|AT × − 3.25)+(RAPH1|57074|AT × 2.73)+(SMAD2|45450|AT × − 2.81)+(TMEM194B|56572|AT × − 10.03)+(PDE4DIP|4410|AT × 1.73)+(CTCFL|59908|AT × − 1.3)+(LYRM2|77010|AT × 11.22)+(C14orf159|28842|AT × 2.38)

2.691 (2.019–3.588)

0.727

ES

(RHOT1|40176|ES × − 3.19)+(NPHP3|66813|ES × 0.96)+(FKTN|87134|ES × − 1.61)+(DEF8|38194|ES × − 2.08)+(CORO1B|387277|ES × − 0.65)+(ACAD10|24535|ES × − 11.34)+(SLC19A2|8922|ES × − 5.85)+(SSR2|8154|ES × − 4.18)+(RANBP3|46967|ES × − 2.17)+(GALNT14|53131|ES × − 11.11)+(POLDIP3|62524|ES × 19.11)+(PAM|72890|ES × 3.45)

3.308 (2.457–4.455)

0.727

ME

(FYN|77273|ME × 1.19)+(NPIPA8|121053|ME × 2.9)+(CTSB|82667|ME × 10.62)+(COX14|101733|ME × 1.2)+(IL1RN|95654|ME × 0.82)+(CNOT10|63822|ME × − 2.44)+(UBR2|127390|ME × − 3.37)

2.355 (1.763–3.145)

0.643

RI

(ABCC5|67820|RI × − 0.71)+(KAT8|36242|RI × − 2.81)+(RBMX|90220|RI × − 1.03)+(CYHR1|85619|RI × − 0.87)+(SALL2|26605|RI × − 3.1)+(DHRS12|25952|RI × − 2.38)+(LAMTOR5|4114|RI × − 0.93)+(NAP1L1|23474|RI × − 1.73)

2.274 (1.711–3.021)

0.729

ALL

(RHOT1|40176|ES × − 2.85)+(SH3KBP1|88642|AP × − 1.07)+(AGTRAP|670|AA × − 1.28)+(SH3KBP1|88643|AP × 0.59)+(PACS2|29633|AP × − 2.14)+(RBPMS|83289|AT × 2.17)+(B3GNTL1|44424|AP × 0.68)+(MOBP|64191|AT × − 1.18)+(NPHP3|66813|ES × 0.67)+(ABCC5|67820|RI × − 1.01)+(FKTN|87134|ES × − 2.54)+(FKBP8|48446|AA × − 6.71)

3.473 (2.572–4.689)

0.743

  1. AS, alternative splicing; HR, hazard ratio; AUC, area under curve; AA, alternate acceptor; AD, alternate donor sites; AP, alternate promoters; AT, alternate terminators; ES, exon skips, ME, mutually exclusive exons; RI, retained introns; ALL, all types